source
- UniQure crashes as Huntington’s gene therapy shows less slowing of disease at 4 yearsThe results are nevertheless “unprecedented,” UniQure executives said on an investor call Tuesday, emphasizing that the updated natural history database used as the control group for the Phase 1/2…BioSpace · 1mo ago↗ source
- Merck pulls Recarbrio antibiotic from U.S. market, raising concerns over superbug resistanceMerck announced it has stopped supplying Recarbrio in the United States earlier this month. Recarbrio, a three‑drug combination injection approved seven years ago, is used for severe infections su…
- AbbVie receives FDA approval for Parkinson’s drug Juvmo, a Cerevel acquisition asset